Overactive Bladder Treatment Market by Pharmacotherapy (Anticholinergic- Solifenacin, Oxybutynin, Fesoterodine, Darifenacin; Mirabegron; BOTOX; Neurostimulation), Disease Type (Idiopathic and Neurogenic Bladder Overactivity) - Global Forecast to 2022

The overactive bladder treatment market includes various therapies, namely, anticholinergics, mirabegron, BOTOX, and neurostimulation used to treat the sudden, involuntary contraction of the muscle in the urinary bladder wall leading to urinary urgency, frequency, nocturia, and urge-incontinence. The global Overactive Bladder Treatment market is projected to be valued at USD 3.63 Billion in 2017 and is expected to grow at a CAGR of 2.9% during the forecast period to reach to USD 4.19 Billion by 2022. Base year considered for the report is 2016. The development of innovative intravesical therapies, aggressive marketing by pharma companies, and favorable demographics are the key factors driving the growth of the Overactive Bladder Treatment market.

Objectives of the Study

• To define, describe, and forecast the global Overactive Bladder Treatment market on the basis of pharmacotherapy, disease type, and region
• To provide detailed information regarding the major factors influencing growth of the Overactive Bladder Treatment market (drivers, restraints, trends, opportunities, and challenges)
• To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the global market
• To analyze the opportunities in the Overactive Bladder Treatment market for stakeholders and provide details of the competitive landscape for market leaders
• To forecast the size of the market segments with respect to four main regions/countries, namely, the U.S., Europe, Asia-Pacific, and the Rest of the World (RoW)
• To profile the key players in the global Overactive Bladder Treatment market and comprehensively analyze their market shares and core competencies
• To track and analyze competitive developments of key players in the global Overactive Bladder Treatment market

Research Methodology

Top-down and bottom-up approaches were used to validate the size of the global Overactive Bladder Treatment market and estimate the size of other dependent submarkets. Various secondary sources such as associations, including American Urology Association, National Center for Biotechnology Information, U.S. National Library of Medicine, European Association of Urology, Urology Care Foundation, National Association For Continence, National Institutes of Health (NIH), Pharmaceutical Research and Manufacturers of America, Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), directories, industry journals, databases, and annual reports of the companies have been used to identify and collect information useful for the study of Overactive Bladder Treatment market. Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess dynamics of Overactive Bladder Treatment market. The breakdown of profiles of primaries is shown in the figure below:

To know about the assumptions considered for the study, download the pdf brochure

The major players in the global overactive bladder treatment market are Astellas Pharma, Inc. (Japan), Pfizer, Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (U.S.), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Sanofi (France), Aurobindo Pharma Limited (India), Apotex, Inc. (Canada), and Cogentix Medical, Inc. (U.S.).

Target Audience:

• Drug manufacturers, vendors, and distributors
• Academic and government research institutes
• Contract manufacturing organizations (CMOs) and contract research organizations (CROs)
• Venture capitalists and investors

Scope of the Report:

The research report categorizes the global market into the following segments and subsegments:

Overactive Bladder Treatment Market, by Pharmacotherapy

• Anticholinergics
• Solifenacin
• Oxybutynin
• Darifenacin
• Fesoterodine
• Tolterodine
• Trospium
• Other Anticholinergics*
• Mirabegron
• BOTOX
• Neurostimulation

*Other anticholinergics include imidafenacin, emepronium, flavoxate, meladrazine, terodiline, propiverine, and desfesoterodine.

Overactive Bladder Treatment Market, by Disease Type

• Idiopathic Bladder Overactivity
• Neurogenic Bladder Overactivity

Overactive Bladder Treatment Market, by Region/Country

• U.S.
• Europe
  • EU-5
  • Rest of Europe (RoE)
• Asia-Pacific
  • Japan
  • Rest of Asia-Pacific (RoAPAC)
• RoW

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

• Further breakdown of the EU-5 overactive bladder treatment market into the Germany, the U.K., France, Italy, and Spain

Company Information

• Detailed analysis and profiling of additional market players (Up to 5)

Table of Contents

1 Introduction
    1.1 Objective of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered in the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders
    1.7 Assumptions

2 Research Methodology
    2.1 Research Methodology Steps
    2.2 Research Design
    2.3 Market Size Estimation
    2.4 Data Triangulation Methodology
    2.5 Market Share Estimation
           2.5.1 Key Data Points Taken From Secondary Sources
           2.5.2 Key Data Points Taken From Primary Sources
                    2.5.2.1 Key Industry Insights

3 Executive Summary

4 Market Overview
    4.1 Introduction
    4.2 Drivers
           4.2.1 Development of Innovative Intravesical Therapies
           4.2.2 Aggressive Marketing By Pharma Companies
           4.2.3 Aging Population and Rising Incidence of Diseases Characterized By OAB
    4.3 Restraints
           4.3.1 Undesired Systemic Effects of Current OAB Treatments
    4.4 Opportunities
           4.4.1 Novel Treatments, Robust Pipeline, and Patent Cliff of Certain Drugs
    4.5 Challenges
           4.5.1 Lack of Awareness on OAB

5 Global Overactive Bladder Treatment Market, By Pharmacotherapy
    5.1 Introduction
    5.2 Anticholinergics
           5.2.1 Solifenacin
           5.2.2 Oxybutynin
           5.2.3 Fesoterodine
           5.2.4 Darifenacin
           5.2.5 Tolterodine
           5.2.6 Trospium
           5.2.7 Other Anticholinergics
    5.3 Mirabegron
    5.4 Botox
    5.5 Neurostimulation
    5.6 Intravesical Instillation

6 Global Overactive Bladder Treatment Market, By Disease
    6.1 Introduction
    6.2 Idiopathic Overactive Bladder 
    6.3 Neurogenic Overactive Bladder
           6.3.1 Introduction
           6.3.2 Overactive Bladder in Parkinson's Disease
           6.3.3 Overactive Bladder in Stroke
           6.3.4 Overactive Bladder in Multiple Sclerosis
           6.3.5 Overactive Bladder in Spinal Cord Injury
           6.3.6 Overactive Bladder in Other Disorders

7 Global Overactive Bladder Treatment Market, By Region
    7.1 Introduction
    7.2 U.S.
           7.2.1 Favorable Reimbursement
           7.2.2 Strong Pharma Industry and Significant Marketing Efforts
           7.2.3 Favorable Demographics of Population at Risk
           7.2.4 Initiatives to Increase Awareness on OAB
    7.3 Europe
           7.3.1 Introduction
           7.3.2 EU-5
                    7.3.2.1 Industry Dynamics
                    7.3.2.2 Demographics and OAB Prevalence
                    7.3.2.3 Attractive Healthcare Sector
                    7.3.2.4 Favorable Reimbursement Policies
                    7.3.2.5 Other Factors
           7.3.3 Rest of Europe
    7.4 Asia-Pacific
           7.4.1 Introduction
           7.4.2 Japan
           7.4.3 Rest of Asia-Pacific
    7.5 Rest of the World (RoW)

8 Marketed Products
    8.1 Marketed Products for Overactive Bladder Syndrome in the U.S. 
    8.2 Marketed Products for Overactive Bladder Syndrome in EU-5 

9 Pipeline Products
    9.1 Pipeline Products for Overactive Bladder Syndrome in the U.S. 
    9.2 Pipeline Products for Overactive Bladder Syndrome in EU-5 

10 Drug Profiles
     10.1 Darifenacin
     10.2 Fesoterodine
     10.3 Oxybutynin
     10.4 Solifenacin
     10.5 Tolterodine
     10.6 Trospium
     10.7 Injection Botox

11 Company Profiles
(Overview, Strength of Product Portfolio Business Strategy Excellence Products Offering, Recent Development’s, Business Strategy)*
     11.1 Astellas Pharma Inc.
     11.2 Pfizer, Inc. 
     11.3 Teva Pharmaceutical Industries Limited 
     11.4 Allergan, PLC. 
     11.5 Mylan N.V. 
     11.6 Endo International PLC 
     11.7 Hisamitsu Pharmaceutical Co., Inc.
     11.8 Sanofi
     11.9 Aurobindo Pharma Limited 
     11.10 Johnson & Johnson
     11.11 Intas Pharmaceuticals Ltd. 
     11.12 Apotex Inc. 
     11.13 Macleods Pharmaceuticals Ltd. 
     11.14 Medtronic PLC
     11.15 Cogentix Medical, Inc. 

*Details on Overview, Strength of Product Portfolio Business Strategy Excellence Products Offering, Recent Development’s, Business Strategy Might Not Be Captured in Case of Unlisted Companies.

12 Appendix
     12.1 Insights of Industry Experts 
     12.2 Discussion Guide 
     12.3 Knowledge Store: Marketsandmarkets’ Subscription Portal 
     12.4 Introducing RT: Real-Time Market Intelligence 
     12.5 Available Customizations
     12.6 Related Reports
     12.7 Authors Details

List of Tables (53 Tables)

Table 1 Global Overactive Bladder Treatment Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 2 Indicative List of Anticholinergics Used in OAB Treatment
Table 3 Global Anticholinergics Market for Overactive Bladder Treatment, 2015–2022 (USD Million)
Table 4 Global Anticholinergics Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 5 Solifenacin Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 6 Oxybutynin Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 7 Fesoterodine Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 8 Darifenacin Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 9 Tolterodine Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 10 Trospium Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 11 Other Anticholinergics Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 12 Mirabegron Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 13 Botox Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 14 Neurostimulation Market for Overactive Bladder Treatment, By Country/Region, 2015–2022 (USD Million)
Table 15 Global Overactive Bladder Treatment Market, By Disease Type, 2015–2022 (USD Million)
Table 16 Global Idiopathic Market, By Country/Region, 2015–2022 (USD Million)
Table 17 Global Neurogenic Market, By Disease, 2015–2022 (USD Million)
Table 18 Global Neurogenic Market, By Country/Region, 2015–2022 (USD Million)
Table 19 Global Market for Parkinson’s Disease, By Country/Region, 2015–2022 (USD Million)
Table 20 Global Market for Stroke, By Country/Region, 2015–2022 (USD Million)
Table 21 Global Market for Multiple Sclerosis, By Country/Region, 2015–2022 (USD Million)
Table 22 Global Market for Spinal Cord Injuries, By Country/Region, 2015–2022 (USD Million)
Table 23 Global Market for Other Disorders, By Country/Region, 2015–2022 (USD Million)
Table 24 Market, By Country/Region, 2015–2022 (USD Million)
Table 25 U.S.: Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 26 U.S. Market, By Disease Type, 2015–2022 (USD Million)
Table 27 Europe: Market, By Country/Region, 2015–2022 (USD Million)
Table 28 Europe: Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 29 Europe: Market, By Disease Type, 2015–2022 (USD Million)
Table 30 EU-5: Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 31 EU-5: Market, By Disease Type, 2015–2022 (USD Million)
Table 32 RoE: Overactive Bladder Treatment Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 33 RoE: Market, By Disease Type, 2015–2022 (USD Million)
Table 34 APAC: Overactive Bladder Treatment Market, By Country/Region, 2015–2022 (USD Million)
Table 35 APAC: Overactive Bladder Treatment Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 36 APAC: Overactive Bladder Treatment Market, By Disease Type, 2015–2022 (USD Million)
Table 37 Japan: Overactive Bladder Treatment Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 38 Japan: Overactive Bladder Treatment Market, By Disease Type, 2015–2022 (USD Million)
Table 39 RoAPAC: Overactive Bladder Treatment Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 40 RoAPAC: Overactive Bladder Treatment Market, By Disease Type, 2015–2022 (USD Million)
Table 41 RoW: Market, By Pharmacotherapy, 2015–2022 (USD Million)
Table 42 RoW: Overactive Bladder Treatment Market, By Disease Type, 2015–2022 (USD Million)
Table 43 U.S.: Marketed Products in Global Overactive Bladder Treatment Market
Table 44 EU-5: Marketed Products in Global Overactive Bladder Treatment Market
Table 45 U.S.: Pipeline Products in Global Overactive Bladder Treatment Market
Table 46 EU-5: Pipeline Products in Global Overactive Bladder Treatment Market
Table 47 Drug Profile: Darifenacin
Table 48 Drug Profile: Fesoterodine
Table 49 Drug Profile: Oxybutynin
Table 50 Drug Profile: Solifenacin
Table 51 Drug Profile: Tolterodine
Table 52 Drug Profile: Trospium
Table 53 Drug Profile: Botox (Onabotulinumtoxina)

List of Figures (39 Figures)

Figure 1 Overactive Bladder Treatment Market
Figure 2 Years Considered for Study – 2017: Estimated Year, 2022: Projected Year
Figure 3 Research Methodology: Secondary Research, Primary Research, and Market Breakdown Steps
Figure 4 Research Design
Figure 5 Secondary Research
Figure 6 Market Size (USD) Estimation Methodology
Figure 7 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 8 Data Triangulation Methodology
Figure 9 Overactive Bladder Treatment: Market Overview (USD Billion)
Figure 10 Global Market, By Pharmacotherapy (USD Million)
Figure 11 Global Market, By Disease Type (USD Million)
Figure 12 Global Neurogenic Market, By Diseases (USD Million)
Figure 13 Geographical Snapshot of the Global Market
Figure 14 Global Market: Drivers, Restraints, Opportuniities, and Challenges
Figure 15 Geriatric Population (Aged 60 and Above) Percentage in 2015 & 2030
Figure 16 Overactive Bladder Treatment Market Segmentation By Pharmacotherapy
Figure 17 Overactive Bladder Diagnosis and Treatment
Figure 18 Global Market Segmentation By Disease Type
Figure 19 Estimated OAB Prevalence in the U.S. and EU-5 (2015)
Figure 20 Prevalence of MS Per 100,000 Individuals
Figure 21 Overactive Bladder Treatment Market in RoAPAC to Grow at the Highest Rate (2017–2022)
Figure 22 U.S.: Branded vs Generic Prescription Drug Revenues (2011-2016)
Figure 23 U.S.: Elderly Population (Aged 65 Years and Above)
Figure 24 U.S.: Obese Population (BMI ≥ 30)
Figure 25 U.S.: National Health Expenditure as % of GDP
Figure 26 Germany Healthcare Expenditure as A % of GDP
Figure 27 Italy: Public and Private Healthcare Spending
Figure 28 Astellas Pharma, Inc.: Company Snapshot (2016)
Figure 29 Pfizer, Inc.: Company Snapshot (2016)
Figure 30 Teva Pharmaceutical Industries Limited: Company Snapshot (2016)
Figure 31 Allergan, PLC: Company Snapshot (2016)
Figure 32 Mylan N.V.: Company Snapshot (2016)
Figure 33 Endo International PLC: Company Snapshot (2016)
Figure 34 Hisamitsu Pharmaceutical Co., Inc.: Company Snapshot (2015)
Figure 35 Sanofi: Company Snapshot (2016)
Figure 36 Aurobindo Pharma Limited: Company Snapshot (2015)
Figure 37 Johnson & Johnson: Company Snapshot (2016)
Figure 38 Medtronic PLC: Company Snapshot (2016)
Figure 39 Cogentix Medical, Inc.: Company Snapshot (2016)

The global overactive bladder treatment market is projected to reach USD 4.19 Billion by 2022 from USD 3.63 Billion in 2017, at a CAGR of 2.9%. The growth of Overactive Bladder Treatment market is majorly driven by the increasing geriatric population and consequently rising prevalence of bladder overactivity, aggressive marketing strategies by pharma companies, and the development of new therapies to treat bladder overactivity. However, the undesired systemic effects caused by anticholinergics may hinder the growth of the Overactive Bladder Treatment market to a certain extent.

Therapy approvals are regulated by various regional regulatory authorities. The changing regulatory scenario favoring overactive bladder treatments in a number of countries, such as the U.K. and Japan, will offer significant growth opportunities for Overactive Bladder Treatment market players. For example, the U.K.’s National Institutes for Health and Care Excellence (NICE) reimburses the BOTOX therapy. In 2007, the Japanese Ministry of Health, Labour and Welfare (MHLW) launched an action plan to promote the safe use of generics.

The report analyzes the Overactive Bladder Treatment market by pharmacotherapy, disease type, and region. On the basis of pharmacotherapy, the anticholinergics segment accounted for the largest share in 2016, being the first line of medical treatment on bladder overactivity. Based on disease type, the idiopathic overactive bladder treatment segment accounted for the largest share in 2016. The high share of this segment can be attributed to its high prevalence; women are more susceptible to the condition owing to bladder muscle weakness post pregnancy and menopause.

Geographically, the global Overactive Bladder Treatment market is segmented into the U.S., Europe, Asia-Pacific, and the Rest of the World. In 2016, the U.S. dominated the Overactive Bladder Treatment market and this is primarily attributed to its well-established healthcare industry with favorable reimbursement of overactive bladder treatment, growing prevalence of the disease with rising age, and the presence of major players. The Rest of Asia-Pacific region is expected to witness the highest CAGR during the forecast period owing to rising prevalence of bladder overactivity, increasing geriatric population, rising healthcare expenditure, and growing awareness on overactive bladder.

In 2016, Astellas Pharma, Inc. (Japan) and Pfizer, Inc. (U.S.) dominated the global Overactive Bladder Treatment market. Some of the other players competing in Overactive Bladder Treatment market are Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (U.S.), Endo International Plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Sanofi (France), Aurobindo Pharma Limited (India), Apotex, Inc. (Canada), and Cogentix Medical, Inc. (U.S.).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst